Abstract Number: PB1971
Meeting: ISTH 2020 Congress
Background: Endothelial cell markers such as soluble thrombomodulin, (STH) and plasminogen activator inhibitor type-1 (PAI-1) among many others, are circulating molecules synthesized in various amounts by the endothelium. Assessment of such markers in diabetic subjects on treatment would reveal the extent of hemostatic complications taking place in the given population.
Aims: The study is aimed at providing information on plasminogen activator inhibitor type-1 and soluble thrombomodulin levels of diabetes mellitus type 2 subjects based on glycemic control.
Methods: The subjects were made up of ninety diabetes mellitus type 2 subjects aged 35-75 years attending clinic at University of Calabar Teaching Hospital with ninety age and sex-matched non-diabetic control subjects. Ethical approval was obtained from the Health Research Ethical Committee (HREC) of the hospital. Bio-data and related information were obtained using a well-structured questionnaire. Each participant in the research gave informed consent. Seven milliliters of venous blood were collected from each participant for analyses of glycated hemoglobin by ion exchange resin method. PAI-1 and STH were assayed by enzyme-linked immunosorbent assay method. Data analysis was done using SPSS version 22.0. Student t-test was used to compare means between test and control subjects. Statistical significance was drawn at p≤ 0.05.
Results: More females than males were affected with type 2 diabetes in the research. HbA1c, PAI-1 and STH were significantly higher than the control subjects (Table 1).
Figure 1 shows increasing mean values of STH and PAI-1 as glycemic control is challenged.
Conclusions: This research observed marked endothelial dysfunction among diabetics in the study locality as evidenced by significantly increased STH and PAI-1 levels based on the degree of glycemic control. For better management of diabetic subjects in this locality, it may be necessary to incorporate PAI-1 and STH as first line tests.
|Parameters||Diabetic Subjects n=90 (100%)||Control Subjects n=90 (100%)||P-value (P≤0.05)|
|Males||23 (25.6)||23 (25.6)|
|Females||67 (74.4)||67 (74.4)|
|Normal glycemic control (˂6.0%)||14 (15.6)||90 (100)|
|Good glycemic control (6.0-6.8%)||7 (7.8)||0|
|Fair glycemic control (6.8-7.65%)||18 (20.0)||0|
|Poor glycemic control (˃7.65%)||51 (56.7)||0|
[Endothelial cell markers and glycemic control of diabetic and non-diabetic subjects]
To cite this abstract in AMA style:Edem MS, Akwiwu EC, Akpotuzor JO. Elevated Plasminogen Activator Inhibitor Type-1 and Soluble Thrombomodulin of Type 2 Diabetes Mellitus Subjects with Increasing Loss of Glycemic Control in Calabar, Southern Nigeria [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/elevated-plasminogen-activator-inhibitor-type-1-and-soluble-thrombomodulin-of-type-2-diabetes-mellitus-subjects-with-increasing-loss-of-glycemic-control-in-calabar-southern-nigeria/. Accessed January 27, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/elevated-plasminogen-activator-inhibitor-type-1-and-soluble-thrombomodulin-of-type-2-diabetes-mellitus-subjects-with-increasing-loss-of-glycemic-control-in-calabar-southern-nigeria/